The impact of multiple sclerosis relapse treatment on migration of effector T cells – Preliminary study by Jatczak-Pawlik, Izabela et al.
Original research article
The impact of multiple sclerosis relapse treatment
on migration of effector T cells – Preliminary study
Izabela Jatczak-Pawlik a,1, Dominika Książek-Winiarek a,b,1,*,
Dagmara Wojkowska a,b, Krzysztof Jóźwiak a,b, Karol Jastrzębski b,
Mirosława Pietruczuk c, Andrzej Głąbiński a,b
aDepartment of Propedeutics of Neurology, Medical University of Lodz, Lodz, Poland
bDepartment of Neurology and Stroke, Medical University of Lodz, Lodz, Poland
cDepartment of Laboratory Diagnostics, Medical University of Lodz, Lodz, Poland
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 1 5 5 – 1 6 2
a r t i c l e i n f o
Article history:
Received 3 December 2015
Accepted 10 February 2016
Available online 20 February 2016
Keywords:
Methylprednisolone
Multiple sclerosis
Migration
Chemokines
Chemokine receptors
a b s t r a c t
Migration of inﬂammatory cells from the blood to the central nervous system (CNS) is crucial
for development of multiple sclerosis (MS). Inhibition of this process would allow to control
disease activity. The ﬁrst step conﬁrming this approach would be the analysis of the impact
of effective MS relapse therapy on migration of effector T cells. The aim of the study was to
analyze the inﬂuence of methylprednisolone (MP) on the migratory activity of effector CD4+
T cells from MS patients. Moreover, to study the potential mechanism of this process we
studied expression of chemokine receptors on migrating cells.
Material and methods: Peripheral blood samples were obtained from relapsing-remitting MS
(RR-MS) patients during relapse (n = 23) and from control group (n = 23). After isolation CD4+
T cells were incubated with various concentrations of MP. Then they were stimulated in
chemotaxis assay with chemokines CCL3 or CXCL10 or were used to CCR1 and CXCR3
expression analysis.
Results: CXCL10- and CCL3-stimulated migration of CD4+ T cells was signiﬁcantly increased
in MS. MP was able to reduce in vitro migration of effector T cells induced by CXCL10, but not
by CCL3. Inhibition by MP was dose-dependent. Expression of analyzed chemokine receptors
was unaltered after MP incubation.
Conclusions: MP reduced CD4+ T cells migration induced by CXCL10 without affecting CXCR3
expression. These observations demonstrate one of the potential mechanisms of MP action
in MS, distinct from inducing cell apoptosis, and suggests the new targets for development of
more effective MS treatments.
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Multiple sclerosis (MS) is considered as an autoimmune
disease of the central nervous system (CNS) [1]. Although
the initial process leading to its development is still not
known, it is highly suggested that the transmigration of
effector cells, especially T cells and monocytes, through the
blood–brain barrier (BBB) to the CNS, is one of the most
important events. The extravasation of inﬂammatory cells
from the blood to the CNS is regulated by adhesion
molecules, cytokines and chemokines [2]. The attack of
the inﬂammatory effector cells on the CNS leads to
demyelination, gliosis, axonal degeneration and develop-
ment of MS clinical signs [3].
Chemokines constitute a large family of small chemoat-
tractant cytokines that share important structural features
and ability to attract leukocytes [4]. Chemokines function
through speciﬁc interaction with chemokine receptors, which
belong to the seven-transmembrane G protein-coupled recep-
tor family mediating a variety of leukocyte responses includ-
ing chemotaxis and immune activation [5]. It is conﬁrmed that
differential spatial and temporal chemokine production by
speciﬁc cell types serves as an important effector and
regulatory mechanism in the pathogenesis of experimental
allergic encephalomyelitis (EAE), an animal model of MS, by
directing mononuclear cell inﬁltration and trafﬁcking within
the CNS [6]. CCL3 is one of the chemokines produced in the
CNS perivascular space that direct inﬂammatory cell migra-
tion toward inﬂammatory foci. Migrating cells produce other
cytokines that stimulate astrocytes localized at the glial
limitans to produce other chemokines, like CXCL10, guiding
leukocytes further toward the brain parenchyma [6]. CXCL10
production by activated astrocytes is postulated to be an
important factor involved also in the induction of antigen
speciﬁc T cells responsible for epitope spreading and mono-
cytes/macrophages that are the end stage effector cells
responsible for axon demyelination and direct axonal tran-
section [6].
The main treatment goal for MS is to reduce number of
disease relapses, prevent new attacks as well as to inhibit
disability progression [1]. In the last several years there has
been a major progress in development of new MS treatments
but their effectiveness is still unsatisfactory. The standard and
effective drug used in MS relapse is still methylprednisolone
(MP) [7]. The mechanism of MP action in MS is complex and
requires further studies. MP is a steroid immunosuppressant
that reduces inﬂammatory tissue edema and myelin break-
down [8]. One of its main mechanism of action is induction of T
cell apoptosis [9,10]. Moreover, MP may switch the immuno-
logical response from Th1 to Th2 cytokine proﬁle [11].
However, it was shown recently that MP may exert its
therapeutic effect independently from apoptosis, through
the alteration of migratory capacity of T cells toward
chemokines, like CXCL12 [12].
The aim of this study was to analyze the ability of MP to
modulate the migratory potential of inﬂammatory effector
cells during active MS. Particularly, we analyzed the impact
of MP on CXCL10- and CCL3-induced migration of CD4+ T cells
isolated from relapsing-remitting MS patients (RR-MS).Moreover, to study the mechanism of this inﬂuence, expres-
sion of chemokine receptors for these ligands (respectively
CXCR3 and CCR1) was also studied.
2. Material and methods
2.1. Patients
All procedures conducted in this study involving human
participants were approved by the Local Bioethics Committee.
Informed consent was obtained from all individual partici-
pants at the beginning of the study.
Peripheral blood samples were obtained from untreated
patients with RR-MS during relapse (total of 23) and patients
with other non-inﬂammatory neurological disorders (OND)
(total of 23, control group). The control OND group consisted of
patients with stroke, subarachnoid hemorrhage, epilepsy,
brain trauma, migraine, Parkinson's disease, vertigo and
vertebral column degeneration. All patients were hospitalized
at the Department of Propedeutics of Neurology and the
Department of Neurology and Stroke, Poland. Blood samples
were collected into vacuum tubes containing heparin as an
anticoagulant.
2.2. PBMCs and CD4+ T cell isolation
Collected blood was diluted (1:1) with phosphate buffered
saline (PBS, Biomed, Lublin, Poland). Peripheral blood mono-
nuclear cells (PBMCs) were separated by gradient centrifuga-
tion using Histopaque-1077 (Sigma–Aldrich, Poznan, Poland)
(450  g, 25 min, 20 8C. The upper phase was removed, PBMCs
from the middle phase were collected into clean tube and the
red blood cells (RBCs) buffer was added for red blood cell lysis
by hypotonic shock (NH4Cl, KHCO3 and Na2EDTA2H2O buffer,
pH 7.2, Sigma, Poznan, Poland) for 5 min at 4 8C. Then PBMCs
were washed with PBS by centrifugation (350  g, 10 min, 4 8C).
PBMCs were resuspended in PBS, counted using Bürker
chamber (Merck, Warsaw, Poland) under a light microscope
(Carl Zeiss, Axio Observer.A1, Poznan, Poland) and used for
isolation of CD4+ T cells with CD4+ T Cell Isolation Kit II human
from Miltenyi Biotec (Bergish Gladbach, Germany).
2.3. In vitro incubation of cells with MP
CD4+ T cells isolated from patients with RR-MS and OND were
cultured in RPMI 1640 medium (PAA, Pasching, Austria)
containing L-glutamine supplemented with 5% fetal calf serum
(FCS) (Sigma, Poznan, Poland), 100 U/ml penicillin and 100 mg/
ml streptomycin (Sigma, Poznan, Poland) at 37 8C in 5% of CO2.
Various concentrations of MP (0.002 mg/ml, 0.02 mg/ml or
0.2 mg/ml) were added to 0.8 mln of CD4+ T cells resuspended
in 1 ml of medium and cultured for 18 h. Control cells (without
addition of MP to the medium) were also cultured for 18 h.
After incubation cells were collected into the clean tube. 5 ml of
CD4+ T cells were resuspended in 40 ml of PBS and stained with
Trypan Blue (5 ml) (Sigma, Poznan, Poland). Cells were counted
under light microscope using Bürker chamber. Subsequently,
appropriate number of cells was used in chemotaxis assay or
ﬂow cytometry analysis.
Fig. 1 – CXCL10- and CCL3-induced chemotaxis of CD4+ T
cells from the blood of MS and control OND patients (n for
MS and OND = 13). Cells were cultured for 18 h in medium
and then in vitro migration stimulated by CXCL10 or CCL3
was analyzed in the transwell system for 3 h as described
in Section 2.
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Chemotaxis assay was conducted in Corning Transwell
Polycarbonate Membrane Insert (Kaysville, UT, USA) consist-
ing of 2 compartments separated by a polyethylene mem-
brane ﬁlter (10.5 mm in diameter with 5-mm pores). 4  105
viable CD4+ T cells from MS or OND patients were resus-
pended in 100 ml of medium (RPMI 1640 with L-glutamine, 5%
FCS – fetal calf serum, 100 U/ml penicillin and 100 mg/ml
streptomycin) and were added to each well of the upper
chamber. The lower chamber was ﬁlled with 600 ml of the
same medium per well. Recombinant human CCL3
(100 ng/ml) (MIP-1alpha, macrophage inﬂammatory protein
1 alpha) or CXCL10 (50 ng/ml) (IP-10, gamma Interferon
inducible Protein 10) were also added to lower chamber
(R&D Systems, Inc., Minneapolis, MN, USA) after optimization
of their concentrations. For each concentration of MP CD4+
T cells from MS or OND patients have migrated to CCL3 (n for
MS and OND = 7) or CXCL10 (n for MS and OND = 6) and
medium (negative control, n for MS and OND = 13). The
migration was conducted in 37 8C at 5% CO2 for 3 h. After this
time the inserts were removed and CD4+ T cells were collected
into small tubes (1.5 ml, Falcon, BD Bioscience, San Jose, CA,
USA). After centrifugation, the supernatant was discarded
and cell pellet was resuspended in 40 ml of PBS and stained
with Trypan Blue (5 ml) (Sigma, Poznan, Poland). All cells were
counted under light microscope using Bürker chamber. The
results of in vitro chemotaxis assay were presented as the
chemotactic index (CI) calculated as chemokine-induced
migration normalized to spontaneous migration of CD4+ T
cells. Medium alone served as a negative control. All
measurements were done in duplicate.
2.5. Chemokine receptors analysis using ﬂow cytometry
CD4+ T cells (0.5  106) isolated from patients with MS (n = 10)
and OND (n = 10) and incubated as described in Section 2.3 with
0.2 mg/ml MP were analyzed. CD4+ T cells without MP
incubation served as a control. Obtained T cells were
resuspended in 100 ml of PBS and incubated with ‘‘FcBlock’’
(BD Bioscience, San Jose, CA, USA) for 15 min at 4 8C. Then
speciﬁc mouse antibodies to human CD45-PE-Cy7, CD4-Paciﬁc
Blue, CCR1-APC and CXCR3-FITC (BD Bioscience, San Jose, CA,
USA) were added at a predetermined optimal concentration
and incubated for 15 min at 4 8C. Cells were washed with 1 ml
of PBS, ﬁxed in 200 ml of 0.4% formaldehyde/PBS and stored at
4 8C until further analysis. The analysis was carried out on
FACS Canto II Instrument (BD Bioscience, Warsaw, Poland) and
the data were analyzed using FACSDiva 6.0 software (BD
Bioscience, Warsaw, Poland).
2.6. Statistical analysis
For statistical analysis, non-parametric Mann–Whitney test
with Bonferroni correction (when needed) was applied.
Correlation coefﬁcient was used to determine correlation of
chemotactic index with concentration of analyzed drug. A
value of p < 0.05 was considered statistically signiﬁcant.
Statistical analysis was performed using Statistica v.8 Soft-
ware.3. Results
3.1. Chemokine-induced migration of CD4+ T cells is
increased in MS patients
CXCL10-induced migration of CD4+ T cells from MS patients
was signiﬁcantly higher (chemotactic index (CI) = 2.75) than in
control group (OND patients; CI = 1.9) (Mann–Whitney test,
p = 0.045). Similarly, CCL3-stimulated migration of CD4+ T cells
from MS patients was higher (CI = 1.5) than in OND patients
(CI = 0.8) (Mann–Whitney test, p = 0.017) (Fig. 1).
3.2. MP reduces CXCL10-induced migration of CD4+ T cells
In vitro preincubation of CD4+ T cells with the highest dose of
MP (0.2 mg/ml) signiﬁcantly reduced their migration in
response to CXCL10 in MS group ( p = 0.004, Mann–Whitney
test) (Fig. 2a). Similarly, only the highest dose of MP was able to
reduce migration of this T cell subpopulation from OND group
( p = 0.004, Mann–Whitney test) (Fig. 2b).
3.3. Reduction of CXCL10-induced migration by MP is
dose-dependent
CXCL10-stimulated migration of CD4+ T cells from MS patients
negatively correlated with concentration of MP in the culture
medium (correlation coefﬁcient = 0.44; p = 0.034) (Fig. 3a).
Similar results were seen for OND group (correlation
coefﬁcient = 0.46; p = 0.02) (Fig. 3b).
Fig. 3 – Correlation between the concentration of MP in
culture medium and inhibition of CXCL10-induced
migration of CD4+ T cells from MS (a) and OND (b) patients
(n for MS and OND = 6). Cells were obtained from the
peripheral blood and preincubated with MP for 18 h. Then
in vitro migration was analyzed in transwell system for 3 h
under stimulation with CXCL10 as described in Section 2
(correlation coefficient: MS (a) = S0.44; p = 0.034) and
control (b) = S0.46; p = 0.02).
Fig. 2 – Reduction of CXCL10-induced chemotaxis of CD4+ T
cells from MS (a) and OND (b) patients (n for MS and
OND = 6) by MP. Before chemotaxis assay cells were
preincubated for 18 h with methylprednisolone (MP).
‘‘Control’’ – migration of CD4+ T cells without
preincubation with MP. In vitro migration was analyzed in
transwell system for 3 h under stimulation with CXCL10.
CD4+ T cells were isolated as described in Section 2.
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T cells
Chemotactic indexes of CCL3-stimulated CD4+ T cells from MS
(Fig. 4a) and OND patients (Fig. 4b) preincubated with MP did
not differ signiﬁcantly.
3.5. MP do not inﬂuence CCR1 and CXCR3 expression on
CD4+ T cells
Chemokine receptors (CCR1 and CXCR3) analyzed in this study
did not show any signiﬁcant alterations in their expression onCD4+ T cells from MS and OND patients after cell incubation
with MP (Fig. 5a, b).
4. Discussion
The blood–brain barrier (BBB) damage and migration of
effector CD4+ T cells from the blood to the central nervous
system (CNS) are the fundamental events in the immuno-
pathogenesis of MS [1]. The process of inﬂammatory cells
recruitment to the CNS comprises several steps from weak
adhesion and rolling on the BBB endothelium, through the ﬁrm
arrest on the luminal side of the endothelium to cell diapedesis
across the BBB to brain parenchyma [13]. Chemokines are
involved in several of these steps, including induction and
activation of leukocyte adhesion molecules that mediate ﬁrm
adhesion of migrating cells to the endothelium, formation of a
chemotactic concentration gradient resulting in migration of
those cells across the endothelial monolayer, and the
Fig. 5 – Effect of methylprednisolone (0.2 mg) on the protein
expression of CCR1 (a) and CXCR3 (b) analyzed on CD4+ T
cells isolated from multiple sclerosis (MS) patients and
patients with other neurological disorders (OND) (n for MS
and OND = 10). The cells were cultured as described in
Section 2. ‘‘Control’’ means that CD4+ T cells were cultured
without this drug.
Fig. 4 – CCL3-induced chemotaxis of CD4+ T cells from MS
(a) and OND (b) patients (n for MS and OND = 7). Cells were
preincubated with methylprednisolone (MP) for 18 h before
the chemotaxis assay. ‘‘Control’’ – migration of CD4+ T cells
without preincubation with MP. In vitro migration was
analyzed in the transwell system for 3 h under stimulation
with CCL3. CD4+ T cells were isolated as described in
Section 2.
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extracellular matrix proteins in the CNS parenchyma [14].
One of the crucial chemokine involved in this process is
CXCL10. Several years ago we and others showed that CXCL10plays an important role in the pathogenesis of animal model of
MS – experimental allergic encephalomyelitis (EAE), mainly in
the recruitment and accumulation of inﬂammatory mononu-
clear cells in the CNS [15–18]. Fife et al. [18] observed that
increasing production of CXCL10 in the CNS precedes the
development of clinical EAE symptoms and maintains high
levels during peak clinical disease. Administration of anti-
CXCL10 antibodies decreased clinical and histological disease
incidence, severity, as well as inﬁltration of mononuclear cells
into the CNS. Anti-CXCL10 treatment speciﬁcally decreased
the accumulation of encephalitogenic PLP139–151 antigen-
speciﬁc CD4+ T cells in the CNS compared to control-treated
animals, but did not affect the activation of encephalitogenic T
cells [18]. Also in the viral model of MS Liu et al. [19] indicated
that CXCL10 promotes CNS demyelination by attracting CD4+
T lymphocytes into the CNS. Further studies conducted on MS
patients also suggested the important role of this chemokine
in the pathogenesis of this disease. The high concentration of
CXCL10 has been detected in the cerebrospinal ﬂuid (CSF) of
MS patients during relapse [20]. In addition, postmortem
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bearing CXCL10 receptor – CXCR3 within inﬂammatory CNS
lesions undergoing demyelination [20].
CCL3 is another crucial player involved in the migration of
inﬂammatory cells to the CNS during development of MS. CCL3
expression in the CNS has been associated with acute disease
symptoms in both rat [21] and mouse [16] EAE models.
Administration of anti-CCL3 antibodies prevented the devel-
opment of acute and relapsing EAE as well as inﬁltration of
lymphocytes into the CNS which was re-initiated by the
adoptive transfer of antigen-speciﬁc effector T cells [22]. CCL3
have been shown to be present not only within inﬂammatory
CNS MS lesions, but also in cerebrospinal ﬂuid of patients with
relapsing-remitting MS [20,23,24]. It is postulated that CCL3
together with CCL5 provide a signal for T cell activation, thus
facilitating antigen presentation [25].
Several studies have suggested that prevention of inﬂam-
matory CD4+ T cells migration from the blood to the CNS
would allow the control of MS activity and should be a target
for future more effective therapies of this disease. An
important step to conﬁrm this approach would be analysis
of the impact of MS relapse treatment on migration of effector
T cells. At present, the standard and relatively effective drug
for MS relapse treatment is methylprednisolone (MP). In this
study we analyzed the potential impact of this drug on in vitro
migratory activity of CD4+ T cells from MS patients induced by
chemokines CXCL10 and CCL3. Moreover, to analyze the
mechanism of this activity we studied the impact of MP on the
expression of CCR1 and CXCR3 (receptors for those chemo-
kines) on migrating cells.
CXCL10-induced migration of CD4+ T cells from MS
patients was signiﬁcantly higher than in control patients.
Moreover, we observed that this migration was signiﬁcantly
inhibited after cell pre-incubation with MP. However, this
effect was not speciﬁc only for MS patients, as it was observed
also in OND group. Only the highest analyzed concentrations
of MP were effective. We observed that the decrease of
migratory activity of effector T cells after incubation with MP
has not been followed by changes of analyzed chemokine
receptors expression. The decrease of migratory activity of
CXCL10-stimulated CD4+ T cells detected after MP incubation
did not induce any change in CXCR3 expression, the only
receptor for CXCL10. This observation suggests that the
mechanism of MP action in MS may be distinct from the
induction of T cells' apoptosis [9,10]. These results may be a
consequence of blocking of some speciﬁc domains of receptor
for CXCL10 on CD4+ T cells by the drug or changing the cell
response machinery to receptor activation by the ligand, what
may result in altered migratory activity of T cells. This
explanation is in line with the study showing that adminis-
tration of anti-CXCL10 antibodies decreased clinical and
histological disease activity in MS model, as well as speciﬁcally
decreased the accumulation of effector encephalitogenic CD4+
T cells in the CNS [18]. As increase in the concentration of
CXCL10 was observed in MS serum [26], CD4+ T cells could be
constantly stimulated in the course of active disease. This
stimulation may increase their ability to cross BBB as we know
that stimulated T cell can easily transmigrate to the CNS. We
conﬁrmed this possibility showing increased migration of
CXCL10-induced CD4+ T cells from MS patients over controls.Another conﬁrmation of our results comes from the study of
Schweingruber et al. [12]. They have demonstrated increased
CXCL12-induced T cell migration after glucocorticoids (GCs)
treatment both in EAE and MS patients. Enhanced T cells
migration to the CXCL12 may results in their accumulation
in the perivascular space, secondary lymphoid and non-
lymphoid organs instead of brain parenchyma [27–29]. As in
our study, Schweingruber and co-workers did not observe any
concurrent changes in CXCR4 surface levels. The authors'
explanation for such phenomenon is that glucocorticoids
(GCs) are able to enhance CXCR4 signaling, rather than its
expression. They have found that GCs have altered cytoskele-
ton rearrangement through the focal adhesion kinase (FAK)
phosphorylation leading to enhanced T cell migration [12].
Importantly, FAK is a part of the CXCR4 signaling pathway
[30,31].
In our study the anti-migratory effect of MP was speciﬁc for
CXCL10-attracted CD4+ T cells. We did not observe any
signiﬁcant inﬂuence of MP on in vitro migration of T cells
after stimulation by CCL3. Furthermore, in our previous study
we have observed signiﬁcant reduction in lymphocytes'
migration induced by CCL5 between cells obtained from MS
patients treated with MP, untreated MS patients or healthy
controls [32]. These data could be the result of some
mentioned above differences in functions of CXCL10, CCL3
and CCL5 in development of perivascular inﬂammatory foci in
the CNS in active phase of MS. They may be also the effect of
various impact of MP on different chemokines.
We have shown that MP has signiﬁcant impact on
migration of activated CD4+ T cells. The mechanism of MP
action is complex so it can target different pathological
processes in MS development. Studies on the effect of MP
on molecules mediating transmigration of inﬂammatory cells
through the BBB showed down-regulation of adhesion
molecules L-selectin, VLA-4 and ICAM. In contrast, expression
of LFA-1 (leukocyte function associated antigen), CD29, CD25,
CD69 and HLA-DR, has not been changed signiﬁcantly [33]. Our
results are partially in line with the observation that MP
treatment can block the BBB crossing by inﬂammatory T cells
through inhibition of their adhesion molecules expression
[33]. However, as for CCL3-induced migration of CD4+ T cells
we did not observe any signiﬁcant changes after MP incuba-
tion, it is rather not the main mechanism of MP action.
Polarization of activated T cells is an important process in
efﬁcient cell migration and adhesion. In polarized cells
lamellipodiae are formed on the leading edge and an uropod
at the opposing pole. Part of the surface molecules, such as
speciﬁc surface receptors, integrins and chemokine receptors
are distributed within these two poles [34]. Such structural
rearrangements are essential for proper T cell movement [35].
Polarized morphology is necessary also for cell–cell interaction
and directional secretion of mediators. By the application of
2-photon microscopy it was discovered that encephalitogenic
T cells change their phenotype to ‘‘migratory’’ one, allowing
cell migration to the target site, the phenomenon important
for EAE development [36]. Müller et al. [37] have shown that
inhibition of T cell migration caused by GCs like MP is related to
morphological alterations. They indicated that GCs induce
T cell depolarization through modulation of cytoskeletal
architecture. In that study T cells were incubated only for
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GCs action on T cells [37]. In our study T cell incubation with
MP lasted for 18 h so another intracellular mechanisms could
be activated leading to inhibition of CXCL10-speciﬁc effector
cell migration. Additionally, studies by Schweingruber et al.
[12] also have indicated that GCs-induced depolarization of
T cells may not be a general process, as they observed various
migratory activity of effector cells depending on the chemoat-
tractant used in the experiment. They have shown that GCs
inhibited T cell migration toward CCL19, but enhanced
CXCL12-induced chemotaxis [12].
The overall conclusion from the ﬁndings presented here is
that MP used as the standard treatment for MS relapse is able
to reduce migratory activity of CD4+ MS T cells induced by
CXCL10. This suggests that effectiveness of MP may be
partially a consequence of its impact on migration of effector
T cells to the CNS. These results give additional insight into the
mechanisms of therapeutic action of MP in MS, however this
phenomenon should be further conﬁrmed in the larger MS
group as the sample size is the main limitation of our study. It
also suggests that targeting migratory activity of CD4+ T cells is
a promising way for development of more effective future MS
therapies.
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